CYRX

ANALYST NOTE: CYROPORT, INC. (CYRX) DATE: 2026-06-13

1. Structural Readiness

Conservative Entry: $12.19 Current Price: $15.01 Extension: +23.1% vs. conservative entry Breakout Level: $12.19 (Conservative Entry)

Classification: CONFIRMED-ACTIVE

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Thesis Status: None Named As of 2026-06-13, there is no named macro or secular thesis attached to this specific setup. This is a tactical, setup-led name. The conviction must be derived strictly from the quality of the structural setup (the confirmed coil) and the immediate business fundamentals disclosed in the most recent earnings and filings. We do not invent a thesis; we judge the name on the strength of the breakout structure and the clarity of the management guidance provided in the evidence base.

3. Business Overview

Company Description: Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions. The company focuses on the storage, handling, and delivery of high-value, temperature-sensitive biological materials, specifically targeting the rapidly growing cell and gene therapy (CGT) market.

Business Model & Segments: The company generates revenue through two primary segments:

• Life Sciences Services: Includes logistics, courier services, and biological specimen management.
• Life Sciences Products: Includes proprietary shipping containers (CryoPort Express Shippers), vacuum insulated dewars, and cryogenic freezer systems.

Key Operational Metrics (as of Q1 2026 / FY2025):

• Revenue Growth: Total revenue for the quarter ended March 31, 2026, was $47.8 million, up from $41.0 million in the prior year period.
• Life Sciences Services revenue: $26.9 million (up from $22.9 million).
• Life Sciences Products revenue: $20.9 million (up from $18.2 million).
• Commercial vs. Clinical Mix: Revenue from commercial cell and gene therapy support grew 26% to $9.1 million, while revenue from clinical trials grew 18% to $12.9 million.
• Pipeline Support: As of March 31, 2026, the company supported a record 766 global clinical trials, a net increase of 55 over the prior year. Of these, 91 were in Phase III.
• Commercial Approvals: The company now supports 21 commercial therapies, up from 20 at the end of 2025. Notably, they supported the accelerated FDA approval of Rocket Pharmaceutical's gene therapy, KRESLADI.

Strategic Expansions & Divestitures:

• Divestiture: On June 11, 2025, the company completed the divestiture of its specialty courier CRYOPDP business to DHL affiliates for $133.0 million, streamlining the focus toward CGT.
• Global Footprint: BioLogistics services commenced in Paris, France, in November 2025. BioServices operations are expected to commence in the fourth quarter of 2026. A new Global Supply Chain Center in Santa Ana, California, is scheduled to open in late 2026.
• Technology: The company utilizes "Cryoportal," a proprietary cloud-based platform for order processing, customs documentation, and real-time shipment tracking, alongside the SmartPak Condition Monitoring System for environmental validation.

4. Archetype and Conviction Analysis

Archetype: Margin Inflector The company fits the "Margin Inflector" archetype. Management has explicitly stated expectations to achieve positive adjusted EBITDA in the second half of 2026, driven by the divestiture of the lower-margin courier business (CRYOPDP) and the scaling of higher-margin commercial CGT support. The shift in revenue mix—where commercial support grew 26% versus 18% for clinical trials—suggests a structural improvement in profitability as the portfolio matures from clinical trials to commercial approvals.

Conviction Stack:

• Thesis Strength: Moderate (Tactical only; no external macro thesis).
• Evidence Quality: High. The evidence base is robust, featuring specific guidance on revenue ($192M–$196M for FY2026), EBITDA inflection, and pipeline growth.
• Structural Quality: High. The ATR at breakout (4.7%) and current ATR (4.3%) fall within the "High" canonical bucket, indicating strong institutional participation and volatility consistent with a confirmed trend.
• Rerating Potential: Moderate to High. The transition to positive EBITDA, combined with the divestiture of non-core assets, positions the company for a multiple expansion if the market re-rates the business from a "growth-at-all-costs" to a "profitable growth" narrative.

Valuation Context: The financial spine indicates forward consensus EPS for FY1 is -0.78 and FY2 is -0.65. While the company is not yet profitable on a GAAP basis, the management guidance for positive *adjusted* EBITDA in H2 2026 is the critical inflection point. The valuation is currently priced on the expectation of this near-term profitability, supported by the $133M cash infusion from the DHL divestiture.

5. Invalidations, Strengtheners, and Gaps

Invalidation Triggers:

• Fundamental Deterioration: A failure to meet the raised FY2026 revenue guidance of $192M–$196M or a delay in achieving positive adjusted EBITDA in H2 2026 would undermine the Margin Inflector thesis.
• Debt Maturity: The $186.2 million in Convertible Senior Notes due in December 2026 presents a refinancing risk if the stock price does not remain supportive or if cash flow does not materialize as expected.

Strengtheners:

• Pipeline Expansion: The guidance to file 10 additional BLA/MAA applications and secure 8 new therapy approvals in the remainder of 2026 would validate the growth narrative.
• Commercial Scaling: Continued growth in the number of supported commercial therapies (currently 21) and the successful ramp-up of the Paris and Santa Ana centers.

Evidence Gaps:

• GAAP Profitability Timeline: While adjusted EBITDA is expected to turn positive, the specific timeline for GAAP net income profitability is not explicitly detailed in the provided evidence, relying on the "adjusted" metric.
• Debt Refinancing Strategy: The evidence confirms the debt maturity date but does not detail the specific strategy for refinancing the $186.2M notes in December 2026 beyond the implied cash from operations and the prior divestiture.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Confirmed active coil structure with price 23% above entry; Management raised FY2026 revenue guidance to $192M-$196M and expects positive adjusted EBITDA in H2 2026; Divestiture of CRYOPDP for $133M has streamlined focus to high-growth CGT market. Key risks: $186.2M convertible notes maturing in December 2026; Dilution risk from convertible debt; Execution risk on new facility openings in Paris and Santa Ana; Potential delay in achieving GAAP profitability. Sizing hint: Position size should reflect the high ATR volatility and the 23% extension; consider scaling in on pullbacks to the breakout zone rather than chasing the current price. Expected path: Management expects continued revenue growth driven by commercial therapy approvals and new facility ramp-ups, with the primary catalyst being the achievement of positive adjusted EBITDA in the second half of 2026. Expected horizon: 6 to 12 months, aligned with the H2 2026 EBITDA inflection and the 2026 revenue guidance realization.